Handelsbanken Fonder Ab Keros Therapeutics, Inc. Transaction History
Handelsbanken Fonder Ab
- $25.3 Billion
- Q3 2024
A detailed history of Handelsbanken Fonder Ab transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 9,700 shares of KROS stock, worth $643,207. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,700
Previous 8,000
21.25%
Holding current value
$643,207
Previous $366,000
53.83%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding KROS
# of Institutions
174Shares Held
30.3MCall Options Held
76.8KPut Options Held
9K-
Black Rock Inc. New York, NY2.51MShares$167 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.9MShares$126 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$123 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.52MShares$101 Million7.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.51MShares$100 Million0.01% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.71B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...